US 11,884,657 B2
PI-kinase inhibitors with anti-infective activity
Jeffrey S. Glenn, Palo Alto, CA (US); Michael A. Gelman, New York, NY (US); Brandon Tavshanjian, San Francisco, CA (US); Kevan Shokat, San Francisco, CA (US); Ingrid Choong, Los Altos, CA (US); and Mark Smith, San Francisco, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US); and The Regents of the University of California, Oakland, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US); and The Regents of the University of California, Oakland, CA (US)
Filed on Jul. 9, 2021, as Appl. No. 17/371,653.
Application 17/371,653 is a continuation of application No. 16/079,025, granted, now 11,091,472, previously published as PCT/US2017/019509, filed on Feb. 24, 2017.
Claims priority of provisional application 62/300,647, filed on Feb. 26, 2016.
Prior Publication US 2022/0017507 A1, Jan. 20, 2022
Int. Cl. C07D 417/12 (2006.01); A61P 31/14 (2006.01); C07D 277/42 (2006.01); C07D 277/44 (2006.01); C07D 277/46 (2006.01); C07D 417/04 (2006.01); C07D 417/14 (2006.01)
CPC C07D 417/12 (2013.01) [A61P 31/14 (2018.01); C07D 277/42 (2013.01); C07D 277/44 (2013.01); C07D 277/46 (2013.01); C07D 417/04 (2013.01); C07D 417/14 (2013.01)] 20 Claims
 
1. A compound having one of formulae (XLVIa)-(XLVId) and (XLVIIa)-(XLVIId):

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
wherein:
R2 is an alkoxy or a substituted alkoxy;
R3 is hydrogen, a lower alkyl or a substituted lower alkyl;
(R)n is one or more optional substituents each independently selected from alkyl, substituted alkyl, hydroxyl, alkoxy, substituted alkoxy, halogen and CO2R″ wherein R″ is hydrogen, alkyl or substituted alkyl;
n is 0, 1, 2, 3, or 4;
Y4 is O;
R41 is lower alkyl; and
R31-R35 are independently selected from hydrogen, methyl, halogen and hydroxy;
or a pharmaceutically acceptable salt thereof.